Cilta-cel Remissions Extend to Five Years

Company Johnson & Johnson / Legend Biotech Event Type Clinical Trial Durability Data Modality CAR-T Cell Therapy (Dual BCMA-Binding Domains) Asset Ciltacabtagene Autoleucel (Cilta-cel / CARVYKTI) Target BCMA Disease Area Early-Line Relapsed or Refractory Multiple Myeloma Summary In the initial 20-patient cohort A subgroup of…